Selskabets formål er at drive handel, produktion, udvikling og rådgivning indenfor den farmaceutiske virksomhed samt andet dermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 22.7 mio. | 21.6 mio. | 336.8 mio. | 313.4 mio. | 1 | |
CVR: 25260279
Secondary names: NATIMMUNE A/S
Compared to 1.006 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
The financial health of AZANTA DANMARK A/S appears robust, with a significant equity position of 313.45 million DKK as of 2024. However, revenue has shown a declining trend from 52.6 million DKK in 2020 to 22.73 million DKK in 2024, indicating a decrease in market demand or operational challenges. Despite this decline, profit margins remain strong, with a profit of 21.57 million DKK in 2024, suggesting effective cost management. The company’s position within the research and experimental development sector is notable, but the declining revenue trend raises concerns about its future growth trajectory.
AI-generated summary
Companies in the same industry and area
CVR 37598194
CVR 46133684
CVR 46429931
CVR 45599124
CVR 33910126
companydata.dk